Related Experiment Video

Updated: Nov 4, 2025

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

7.9K

Hepcidin Levels and Pathological Characteristics in Children with Fatty Liver Disease

Norito Tsutsumi1, Shigeo Nishimata1, Masaru Shimura1,2

  • 1Department of Pediatrics and Adolescent Medicine, Tokyo Medical University, Tokyo, Japan.

Pediatric Gastroenterology, Hepatology & Nutrition
|May 28, 2021
PubMed

Insights

In pediatric nonalcoholic fatty liver disease (NAFLD), higher serum hepcidin levels inversely correlate with liver fibrosis. This suggests reduced liver hepcidin production contributes to fibrosis progression in children with NAFLD.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Biochemistry

Background:

  • Hepcidin levels are linked to liver damage.
  • The relationship between hepcidin and liver fibrosis in pediatric fatty liver disease is not well understood.

Purpose of the Study:

  • To investigate the pathophysiology of liver fibrosis in children with fatty liver disease.
  • To determine the association between hepcidin levels and liver fibrosis in this population.

Main Methods:

  • Retrospective case series of 12 boys (aged 6-17) with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
  • Analysis of 16 liver biopsy samples using enzyme-linked immunosorbent assay for serum hepcidin and immunostaining.
  • Stratification of samples based on hepcidin staining intensity.

Main Results:

  • Pediatric NAFLD/NASH patients exhibited higher serum hepcidin levels compared to controls.
  • A significant inverse correlation was found between hepcidin immunostaining and Brunt grade scores.
  • Inverse correlations were observed between hepcidin scores and liver injury markers (GGT, hyaluronic acid, leukocytes, AST, ALT, total bile acid) and platelet count.

Conclusions:

  • A significant inverse correlation exists between hepcidin immunoreactivity and fibrosis in pediatric NAFLD.
  • Elevated serum hepcidin suggests impaired liver hepcidin production, contributing to fibrosis.
  • Hepcidin levels may serve as potential biomarkers for identifying fibrosis progression in pediatric NAFLD patients.
Abstract

Keywords:
ImmunohistochemistryIronLiver cirrhosisNonalcoholic fatty liver disease

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

252
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
45
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
52
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
49
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
52
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
267